Logo Logo Logo Logo Logo Logo
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development

Sitemap

Pages

  • About us
    • Corporate Social Responsibility
    • Our team
  • Accessibility
  • Advocacy
  • Aegerion Consent Decree
  • Amryt Compliance
  • Business development
  • Contact us
  • Cookie policy
  • Fraud warning
  • Healthcare Professionals
    • Expanded access programme
    • Grants and donations
    • Medical Information Enquiries
    • Research study requests
  • Home
  • Investors
    • AIM Delisting
    • AIM Rule 26
    • Analysts
    • Circulars and admission document
    • Contacts and Advisors
    • Contingent Value Rights (CVR) FAQ
    • Corporate Governance
    • Events
    • Reports
      • Register for email alerts
    • Share price information
  • Join us
  • Newsroom
  • Our science
    • Trials
    • Trials
  • Patient Stories
  • Patients and carers
    • Acromegaly
    • Acromegaly
    • Epidermolysis Bullosa
    • Epidermolysis Bullosa
    • Homozygous Familial Hypercholesterolaemia
    • Lipodystrophy
    • Lipodystrophy
  • Pipeline
  • Privacy
  • Product Portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Oleogel-S10 (birch triterpenes)
  • Sitemap
  • Social Media Guidelines
  • Terms and conditions

Amryt Pharma

We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need.

Privacy policy | Terms and Conditions | Modern Slavery Statement
Cookie policy | Fraud warning
Accessibility | Sitemap

Copyright © 2022 Amryt Pharma plc